How CAR-T therapies shift hemostasis risk remains an active clinical problem. A review in the Journal of Translational Medicine mapped immune-thrombotic mechanisms behind post–CAR-T hemostatic complications, spanning bleeding, arterial and venous thrombosis, disseminated intravascular coagulation, and thrombotic microangiopathy. The authors emphasize overlapping syndromes such as cytokine release syndrome and neurotoxicity that complicate interpretation and baseline hemostatic reserve as key determinants of patient risk.
Get the Daily Brief